Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues

NCT04822688 | Completed

• 2 other identifiers: 21C.030JT 16542
• Study Type: observational
• Target: 141
• Locations: 1 country
• Sites: 1

Brief Summary

This study examines tumor tissues and blood samples to aid in the development of therapies for brain cancer and other solid tumors. Studying samples of blood and tissue from patients with glioblastoma or other solid tumor in the laboratory may help doctors understand brain tumors and better inform future treatments.

Conditions

Glioblastoma; Malignant Solid Neoplasm

Outcome Measures

Primary Outcomes (2)

• Cell yield

  This will be determined for each sample. Cell yield data is measured in 106and is assumed to be normally distributed. Summary statistics of mean, standard deviation, 95% confidence interval and range will be reported.

  At study completion, up to 12 months

• Percentage cell viability

  Percentage cell viability will be calculated by the number of viable cells divided by the cell yield. The mean will be computed using the sum of the viable cells divided by the sum of cell yield. The range of percentage cell viability and 95% confidence interval will be provided.

  At study completion, up to 12 months

Study Arms (1)

Basic Science (Biospecimen collection)

Patients undergo collection of tissue sample during surgery. Patients also undergo collection of blood sample.

Procedure: Biospecimen Collection

Interventions

Biospecimen Collection PROCEDURE

Undergo collection of tissue and blood samples

Basic Science (Biospecimen collection)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with GBM or other solid tumor and undergoing surgery

You may qualify if:

• Provide signed and dated informed consent form
• Any individual \>= 18 years old
• Patients must have GBM or other solid tumor and undergoing surgery for diagnostic and therapeutic purposes

You may not qualify if:

• Individuals less than 18 years old
• Unable to understand and give consent
• Patients who are not surgical candidates

Sponsors & Collaborators

• Thomas Jefferson University: lead

Study Sites (1)

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Tissue, blood

MeSH Terms

Conditions

Glioblastoma

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 4, 2021
• First Posted: March 30, 2021
• Study Start: February 3, 2021
• Primary Completion: June 30, 2025
• Study Completion: June 30, 2025
• Last Updated: February 10, 2026

Record last verified: 2026-02

Locations

US (1)